Immunic, Inc. (NASDAQ:IMUX) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET

Company Participants

Jessica Breu - Head, IR and Communications

Daniel Vitt - CEO and President

Glenn Whaley - CFO

Andreas Muehler - Chief Medical Officer

Conference Call Participants

Andreas Argyrides - Wedbush

Yasmeen Rahimi - Piper Sandler

Matt Kaplan - Ladenburg

Operator

Jessica Breu

Good morning, everyone, and welcome to Immunic's Third Quarter 2022 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic. I will also be the moderator on today's call.

Speaking on the call are Dr. Daniel Vitt, our Chief Executive Officer and President; as well as Glenn Whaley, our Chief Financial Officer. For the Q&A session, we'll also have Dr. Hella Kohlhof; our Chief Scientific Officer, and Dr. Andreas Muehler; our Chief Medical Officer on the line.

[Operator Instructions] This event is being recorded. [Operator Instructions]

Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate or words with the similar meaning, and such statements involve a number of risks and uncertainties that could cause Immunic's actual results to differ materially from those discussed here. Please note that these forward-looking statements reflect Immunic's opinions only as of the date of this presentation and it undertakes no obligation to revise or publicly release the result of any revision to these forward-looking statements in light of new information or future events. Please refer to Immunic's SEC filings for a more detailed description of the risk factors that may affect Immunic's results and these forward-looking statements.

I would now like to turn the call over to our CEO and President, Dr. Daniel Vitt, to open the presentation. Daniel, please go ahead.

Daniel Vitt

Yes. Thank you, Jessica.

I also would like to welcome everybody on Immunic's third quarter 2022 earnings call. Earlier this morning, we announced our financial results for the quarter ended September 30, 2022, and highlighted recent activities as well as upcoming milestones related to our clinical development pipeline.

During today's call, we will walk through our third quarter 2022 and subsequent highlights, financial and operating results as well as anticipated milestones. As Jessica noted before, we close the call, you will have the opportunity to ask questions.

Let me move to a more detailed review of the recent quarter, including our clinical and operational updates. Earlier in the quarter, Jan Van den Bossche decided to step down from our Board of Directors after six years of valuable service. At the same time, we announced the appointment of Maria Tornsen, our industry - an industry executive with 20 years of global commercial experience in the United States in ex-U.S.